102 related articles for article (PubMed ID: 26899980)
1. Tumor targeted delivery of octreotide-periplogenin conjugate: Synthesis, in vitro and in vivo evaluation.
Zhang HY; Xu WQ; Wang YW; Omari-Siaw E; Wang Y; Zheng YY; Cao X; Tong SS; Yu JN; Xu XM
Int J Pharm; 2016 Apr; 502(1-2):98-106. PubMed ID: 26899980
[TBL] [Abstract][Full Text] [Related]
2. Octreotide-periplocymarin conjugate prodrug for improving targetability and anti-tumor efficiency: synthesis, in vitro and in vivo evaluation.
Zhang HY; Xu WQ; Zheng YY; Omari-Siaw E; Zhu Y; Cao X; Tong SS; Yu JN; Xu XM
Oncotarget; 2016 Dec; 7(52):86326-86338. PubMed ID: 27861145
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
4. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
5. Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.
Su Z; Shi Y; Xiao Y; Sun M; Ping Q; Zong L; Li S; Niu J; Huang A; You W; Chen Y; Chen X; Fei J; Tian J
Int J Pharm; 2013 Apr; 447(1-2):281-92. PubMed ID: 23396258
[TBL] [Abstract][Full Text] [Related]
6. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
Li H; Yuan D; Sun M; Ping Q
Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
[TBL] [Abstract][Full Text] [Related]
7. Periplogenin Activates ROS-ER Stress Pathway to Trigger Apoptosis via BIP-eIF2α- CHOP and IRE1α-ASK1-JNK Signaling Routes.
Yang Y; Liu Y; Zhang Y; Ji W; Wang L; Lee SC
Anticancer Agents Med Chem; 2021; 21(1):61-70. PubMed ID: 32640963
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles.
Huo M; Zou A; Yao C; Zhang Y; Zhou J; Wang J; Zhu Q; Li J; Zhang Q
Biomaterials; 2012 Sep; 33(27):6393-407. PubMed ID: 22704599
[TBL] [Abstract][Full Text] [Related]
9. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
10. Octreotide-Mediated Tumor-Targeted Drug Delivery via a Cleavable Doxorubicin-Peptide Conjugate.
Lelle M; Kaloyanova S; Freidel C; Theodoropoulou M; Musheev M; Niehrs C; Stalla G; Peneva K
Mol Pharm; 2015 Dec; 12(12):4290-300. PubMed ID: 26524088
[TBL] [Abstract][Full Text] [Related]
11. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage.
Nakamura H; Etrych T; Chytil P; Ohkubo M; Fang J; Ulbrich K; Maeda H
J Control Release; 2014 Jan; 174():81-7. PubMed ID: 24269967
[TBL] [Abstract][Full Text] [Related]
12. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis.
Huang CM; Wu YT; Chen ST
Chem Biol; 2000 Jul; 7(7):453-61. PubMed ID: 10903942
[TBL] [Abstract][Full Text] [Related]
13. Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the self-assembly supramolecular nanocarrier.
Niu J; Huang A; Xiao Y; Su Z; Li H; Ping Q; Bao X; Li S; Chen Y; Sun M
J Drug Target; 2013 May; 21(5):415-26. PubMed ID: 23597028
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin.
Kim H; Lee Y; Lee IH; Kim S; Kim D; Saw PE; Lee J; Choi M; Kim YC; Jon S
J Control Release; 2014 Mar; 178():118-24. PubMed ID: 24462899
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
Shen H; Hu D; Du J; Wang X; Liu Y; Wang Y; Wei JM; Ma D; Wang P; Li L
Eur J Pharmacol; 2008 Dec; 601(1-3):23-9. PubMed ID: 18983839
[TBL] [Abstract][Full Text] [Related]
16. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
[TBL] [Abstract][Full Text] [Related]
17. A validated LC-MS/MS method for determination of periplogenin in rat plasma and its application in pharmacokinetic study.
Bo F; Dou T; Wang X; Donkor PO; Ouyang H; Chang Y; Tu Y; Gao X; He J
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 990():80-3. PubMed ID: 25864008
[TBL] [Abstract][Full Text] [Related]
18. Periplogenin induces necroptotic cell death through oxidative stress in HaCaT cells and ameliorates skin lesions in the TPA- and IMQ-induced psoriasis-like mouse models.
Zhang WJ; Song ZB; Bao YL; Li WL; Yang XG; Wang Q; Yu CL; Sun LG; Huang YX; Li YX
Biochem Pharmacol; 2016 Apr; 105():66-79. PubMed ID: 26850986
[TBL] [Abstract][Full Text] [Related]
19. Octreotide-conjugated PAMAM for targeted delivery to somatostatin receptors over-expressed tumor cells.
Peng J; Qi X; Chen Y; Ma N; Zhang Z; Xing J; Zhu X; Li Z; Wu Z
J Drug Target; 2014 Jun; 22(5):428-38. PubMed ID: 24437350
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog.
Dubey N; Varshney R; Shukla J; Ganeshpurkar A; Hazari PP; Bandopadhaya GP; Mishra AK; Trivedi P
Drug Deliv; 2012 Apr; 19(3):132-42. PubMed ID: 22428685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
